Navigation Links
NeoTract Designates Dr. Jayant Uberoi as UroLift® Center of Excellence
Date:2/20/2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Jayant Uberoi, MD, Chesapeake Urology in Baltimore MD, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Uberoi has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Jayant Uberoi has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:
Jake Elguicze, 610.948.2836
Treasurer and Vice President, Investor Relations

Media:
Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction
1. Roehrborn, J Urology 2013 LIFT Study
2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Read the full story at https://www.prweb.com/releases/neotract_designates_dr_jayant_uberoi_as_urolift_center_of_excellence/prweb16921230.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine technology :

1. NeoTract Designates Dr. Vi Hua as UroLift® Center of Excellence
2. NeoTract Designates Dr. Patrick P. Daily as UroLift® Center of Excellence
3. NeoTract Designates Dr. T. Casey McCullough as UroLift® Center of Excellence
4. NeoTract Designates Dr. Tony Nimeh as UroLift® Center of Excellence
5. NeoTract Designates Dr. Samuel Dakil as UroLift® Center of Excellence
6. NeoTract Designates Dr. Timothy Lesser as UroLift® Center of Excellence
7. NeoTract Designates Dr. Elizabeth Mobley as UroLift® Center of Excellence
8. NeoTract Designates Dr. Kalpesh Patel as UroLift® Center of Excellence
9. Caris Life Sciences Designates Fox Chase Cancer Center a Caris Center of Excellence in Precision Medicine
10. Caris Life Sciences Designates Virginia Cancer Specialists as a Caris Center of Excellence
11. Caris Life Sciences Designates MedStar Health a Caris Center of Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2020)... ... April 02, 2020 , ... NCPDP has elected its 2020-2021 Board of ... NCPDP Board of Trustees on Wednesday, May 6, 2020. , Election Results – ... Lead, Point-of-Care Partners, newly elected to the Board of Trustees. , Morgan ...
(Date:4/2/2020)... ... 2020 , ... Caitlin Richardson, a University of Washington MEDEX ... Semester Scholarship. , The $1,000 scholarship, awarded biannually to U.S. students who ... helping the students pay tuition and other college-related expenses. , Rhonda Abbe, Director ...
(Date:4/1/2020)... ... April 01, 2020 , ... Care Station Medical Group -- In light ... number of changes to better care for our community. As New Jersey's leading urgent ... crafted new ways to offer medical care to patients coping with COVID-19. , ...
Breaking Medicine Technology:
(Date:4/2/2020)... ... , ... The Northern Virginia Community College Educational Foundation (NOVA Foundation) is proud ... Palm Beach, Florida. Ms. Howe is adding to her existing endowed scholarship fund ... important than ever given the current pandemic. Ms. Howe has also generously donated to ...
(Date:4/2/2020)... , ... April 02, 2020 , ... ... in their mother’s womb are encouraging their parents, grandparents, and guardians, to file ... up to $6 billion in funds will be made available by Purdue as ...
(Date:4/1/2020)... Va. (PRWEB) , ... April 02, 2020 , ... Medical ... 3:00 p.m. EDT, https://www.fdanews.com/mdchangemanagement , What change management method should one ... the method is often dependent on the type of change. Is it due to ...
(Date:4/1/2020)... ... April 01, 2020 , ... ... stay safe while treating Coronavirus-infected patients. , Staffers are in particular need of ... coronavirus. Earlier this week, The Wall Street Journal reported that New York City ...
(Date:4/1/2020)... (PRWEB) , ... April 01, 2020 , ... Global mobile ... and forms for teams adjusting to new needs based on COVID-19. , As cases ... for groups of all types. , Zerion will extend support by offering free basic ...
Breaking Medicine News(10 mins):